Milestone Pharmaceuticals (MIST) Net Income towards Common Stockholders (2018 - 2022)
Milestone Pharmaceuticals (MIST) posted Net Income towards Common Stockholders of -$15.0 million for Q3 2022, up 10.57% on a QoQ basis from -$16.8 million in Q2 2022, and down 5.66% year-over-year from -$15.9 million in Q3 2021.
Milestone Pharmaceuticals (MIST) Net Income towards Common Stockholders (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$15.0 million for Q3 2022.
- Quarterly Net Income towards Common Stockholders fell 5.66% year-over-year to -$15.0 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$15.0 million (up 68.63% YoY) and the FY2021 annual result came in at -$42.9 million, up 14.24% from the prior year.
- Net Income towards Common Stockholders was -$15.0 million for Q3 2022 at Milestone Pharmaceuticals, up from -$16.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $770000.0 in Q2 2021 and bottomed at -$18.3 million in Q4 2019.
- A 5-year average of -$11.3 million and a median of -$12.7 million in 2019 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders soared 105.93% — and 2022, when it tumbled 2282.6%.
- Milestone Pharmaceuticals' Net Income towards Common Stockholders stood at -$9.7 million in 2018, then tumbled by 88.21% to -$18.3 million in 2019, then jumped by 52.61% to -$8.7 million in 2020, then tumbled by 94.83% to -$16.9 million in 2021, then grew by 10.98% to -$15.0 million in 2022.
- Business Quant data shows MIST's Net Income towards Common Stockholders at -$15.0 million in Q3 2022, -$16.8 million in Q2 2022, and -$16.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.11 Bn | 467.32 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.89 Bn | 114.65 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.82 Bn | 50.63 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.49 Bn | 37.49 Bn | - | -453.82 Mn |
| 10 | Milestone Pharmaceuticals | 148.53 Mn | -35.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -15.03 Mn |
| Jun 30, 2022 | -16.81 Mn |
| Dec 31, 2021 | -16.88 Mn |
| Sep 30, 2021 | -14.23 Mn |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -11.98 Mn |
| Jun 30, 2020 | -12.98 Mn |
| Mar 31, 2020 | -16.34 Mn |
| Dec 31, 2019 | -18.29 Mn |
| Sep 30, 2019 | -12.83 Mn |
| Jun 30, 2019 | -13.66 Mn |
| Mar 31, 2019 | -10.45 Mn |
| Dec 31, 2018 | -9.72 Mn |
| Sep 30, 2018 | -5.70 Mn |
| Jun 30, 2018 | -3.59 Mn |
| Mar 31, 2018 | -4.18 Mn |